Development · 27 Aug 2026

Crisil's analysis of 600 deals over Rs 500 crore each across 20 sectors shows that overall acquisitions by India Inc have more than doubled since fiscal year 2017, but one-third of them have not yielded desired outcomes.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

indiatimes.com26 Aug 2026

A single act of reporting so far, corroborating sources join this record as they publish.

CRISIL

₹4,428.60

▼ -0.50%

Close (EOD), as of 1 Oct 2026 · source

CRISIL: results, dividends, orders, the full cited record →

More on CRISIL

Crisil indicated that a potential 0.50 percentage point rate hike by the RBI will have minimal impact on India Inc.

1 Oct 2026 · 1 publisher

Crisil Ratings said India Inc's deleveraged balance sheets and improving credit quality should cushion companies against a possible 50 basis point RBI rate hike and external risks.

30 Sep 2026 · 1 publisher

Crisil Ratings’ credit ratio improved to 2.18 times in the first half of FY27 from 1.50 times in the second half of FY26.

30 Sep 2026 · 1 publisher

India's pharmaceutical sector is poised for a stronger dose of revenue growth at 11-13 percent this fiscal year compared to 8 percent a year earlier, driven by accelerating exports and firmer domestic demand, according to a report by Crisil Ratings.

25 Sep 2026 · 3 publishers

GIC Housing Finance received an affirmation in credit ratings from CRISIL for its various debt facilities including bank facilities, NCDs and commercial paper at CRISIL AA+; Stable / CRISIL A1+.

20 Sep 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.